A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients

Condition:   Metastatic Pancreatic Ductal Adenocarcinoma Intervention:   Drug: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine Sponsors:   Pancreatic Cancer Action Network;   Novartis Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials